Ile/Ile homozygosity at codon 655 of HER2 in schwannoma

Acta Neurologica Taiwanica

Volumn 20, Issue 4, 2011, Pages 243-248

  Wang, Vin Chi ^a,b   Li, Jhy Wei ^c,d   Suen, Jeng Hung ^e   Chuang, Tzu Chao ^f   Kao, Ming Ching ^g  

^a CARDINAL TIEN HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^d Da Chien General Hospital   (Taiwan)

^e Taipei Institute of Pathology   (Taiwan)

^f TAMKANG UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Codon 655 polymorphism; HER2; Ile Ile homozygosity; Schwannoma

Indexed keywords

ALCOHOL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETHYLNITROSOUREA; GENOMIC DNA; ISOLEUCINE; MYELIN; VALINE; XYLENE;

ALLELE; ARTICLE; BLOOD SAMPLING; CARCINOGENESIS; CODON; CONTROLLED STUDY; DNA EXTRACTION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LEUKOCYTE; NEURILEMOMA; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVE; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; SCHWANN CELL;

ADOLESCENT; ADULT; AGED; CODON; FEMALE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; NEURILEMMOMA; RECEPTOR, ERBB-2;

EID: 84863238000     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR. Neurofibromatosis type 2. Lancet 2009;373:1974-1986.
2. Yang I, Sughrue ME, Han SJ, Fang S, Aranda D, Cheung SW, Pitts LH, Parsa AT. Facial nerve preservation after vestibular schwannoma gamma knife radiosurgery. J Neurooncol 2009;93:41-48.
3. Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, Biggerstaff J, Iacovelli J. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 2002; 31:354-362. (Pubitemid 35154443)
4. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358-367.
5. Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, Guha A. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Cancer Res 2009;69:5099- 5107.
6. Frohnert PW, Stonecypher MS, Carroll SL. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line. Glia 2003;43:104-118. (Pubitemid 36897272)
7. Hansen MR, Linthicum FH, Jr. Expression of neuregulin and activation of erbB receptors in vestibular Schwannomas: possible autocrine loop stimulation. Otol Neurotol 2004;25:155-159. (Pubitemid 39079844)
8. Stonecypher MS, Chaudhury AR, Byer SJ, Carroll SL. Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. J Neuropathol Exp Neurol 2006;65:162-175.
9. Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341- 354.
10. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261-264. (Pubitemid 11149660)
11. Nikitin AYu, Ballering LA, Lyons J, Rajewsky MF. Early mutation of the neu (erbB-2) gene during ethylnitrosoureainduced oncogenesis in the rat Schwann cell lineage. Proc Natl Acad Sci U S A 1991;88:9939-9943. (Pubitemid 21915750)
12. Bargmann CI, Weinberg RA. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 1988;7:2043-2052.
13. Stoica G, Tasca SI, Kim HT. Point mutation of neu oncogene in animal peripheral nerve sheath tumors. Vet Pathol 2001;38:679-688. (Pubitemid 33107551)
14. Lee SC, Hou MF, Hsieh PC, Wu SH, Hou LA, Ma H, Tsai SM, Tsai LY. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clin Biochem 2008;41:121-125.
15. Tao W, Wang C, Han R, Jiang H. HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2009;114:371-376.
16. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378:394-398.
17. Birchmeier C. ErbB receptors and the development of the nervous system. Exp Cell Res 2009;315:611-618.
18. Garratt AN, Britsch S, Birchmeier C. Neuregulin, a factor with many functions in the life of a Schwann cell. Bio Essays 2000;22:987-996.
19. Kwon YK, Bhattacharyya A, Alberta JA, Giannobile WV, Cheon K, Stiles CD, Pomeroy SL. Activation of ErbB2 during wallerian degeneration of sciatic nerve. J Neurosci 1997;17:8293-8299. (Pubitemid 27461053)
20. Guertin AD, Zhang DP, Mak KS, Alberta JA, Kim HA. Microanatomy of axon/glial signaling during Wallerian degeneration. J Neurosci 2005;25:3478-3487. (Pubitemid 40471356)
21. Lin W, Sanchez HB, Deerinck T, Morris JK, Ellisman M, Lee KF. Aberrant development of motor axons and neuromuscular synapses in erbB2-deficient mice. Proc Natl Acad Sci USA 2000;97:1299-1304. (Pubitemid 30080853)
22. Vock VM, Ponomareva ON, Rimer M. Evidence for muscle- dependent neuromuscular synaptic site determination in mammals. J Neurosci 2008;28:3123-3130. (Pubitemid 351442281)
23. Patten BA, Peyrin JM, Weinmaster G, Corfas G. Sequential signaling through Notch1 and erbB receptors mediates radial glia differentiation. J Neurosci 2003;23:6132-6140. (Pubitemid 36859451)
24. Gerecke KM, Wyss JM, Carroll SL. Neuregulin-1beta induces neurite extension and arborization in cultured hippocampal neurons. Mol Cell Neurosci 2004;27:379-393. (Pubitemid 39539993)
25. Barros CS, Calabrese B, Chamero P, Roberts AJ, Korzus E, Lloyd K, Stowers L, Mayford M, Halpain S, Müller U. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc Natl Acad Sci U S A 2009;106:4507-4512.
26. Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH. The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol 2009;29:1472-1486.
27. Papewalis J, Nikitin AYu, Rajewsky MF. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 1991;19:5452.
28. Li JW, Chuang TC, Yang AH, Hsu CK, Kao MC. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan. Int J Oncol 2005;26:933-943.
29. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000;92:412-417. (Pubitemid 30154823)
30. Cox DG, Hankinson SE, Hunter DJ. The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics 2005;15:447-450. (Pubitemid 41017592)
31. Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, Huang WY, Geradts J, Iacocca M, Cowan D, Conway K, Dressler L. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 2003;79:355-364. (Pubitemid 36750943)
32. Frank B, Hemminki K, Wirtenberger M, Bermejo JL, Bugert P, Klaes R, Schmutzler RK, Wappenschmidt B, Bartram CR, Burwinkel B. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 2005;26:643-647. (Pubitemid 41214155)
33. Han W, Kang D, Lee JE, Park IA, Choi JY, Lee KM, Bae JY, Kim S, Shin ES, Lee JE, Shin HJ, Kim SW, Kim SW, Noh DY. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res 2005;11:4775-4778.
34. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular- activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A 2002;99:15937-15940. (Pubitemid 35462727)
35. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009;4:16.
36. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, Minna JD. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-1231.
37. Morris ZS, McClatchey AI. Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proc Natl Acad Sci U S A 2009;106:9767-9772.
38. Maitra S, Kulikauskas RM, Gavilan H, Fehon RG. The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol 2006;16:702-709.
39. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 2007;177:893-903. (Pubitemid 46873094)
40. Cole BK, Curto M, Chan AW, McClatchey AI. Localization to the cortical cytoskeleton is necessary for Nf2/merlindependent epidermal growth factor receptor silencing. Mol Cell Biol 2008;28:1274-1284. (Pubitemid 351214130)